Cyclobenzaprine
- Generic Name
- Cyclobenzaprine
- Brand Names
- Amrix, Fexmid, Flexeril
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N
- CAS Number
- 303-53-7
- Unique Ingredient Identifier
- 69O5WQQ5TI
- Background
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from Amitriptyline by only a single double bond. Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
- Indication
用于缓解与急性疼痛的肌肉骨骼疾病相关的肌肉痉挛（作为休息和物理治疗的辅助药）。但环苯扎林对脑、脊髓疾病或儿童脑性瘫痪引起的痉挛无效。
- Associated Conditions
- Muscle Spasms
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT03841773
- Locations
- 🇺🇸
Ashild Peters, Dallas, Texas, United States
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Breastfed Infants of Mothers on Select DOILactating Women on Select DOI
- Interventions
- Drug: Tranexamic acid (TXA)
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03443960
- Locations
- 🇨🇦
Quebec City, Quebec City, Quebec, Canada
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
- Conditions
- Driving Impaired
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Neurana Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03353922
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸NeuroTrials Research, Atlanta, Georgia, United States
Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
- Conditions
- Pain, Acute
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Apsen Farmaceutica S.A.
- Target Recruit Count
- 140
- Registration Number
- NCT03127592
- Locations
- 🇧🇷
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03110575
- Locations
- 🇺🇸
New York, New York, New York, United States
🇺🇸Orange, Orange, California, United States
🇺🇸Rogers, Rogers, Arkansas, United States
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT03062540
- Locations
- 🇺🇸
Chicago, Chicago, Illinois, United States
🇺🇸Lauderhill, Lauderhill, Florida, United States
🇺🇸Maitland, Maitland, Florida, United States
Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment
- Conditions
- Musculoskeletal Pain
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- EMS
- Target Recruit Count
- 416
- Registration Number
- NCT03025113
- Locations
- 🇧🇷
Allegisa, Campinas, São Paulo, Brazil
Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders
- Conditions
- Temporomandibular Disorder
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Instituto Brasileiro de Osteopatia
- Target Recruit Count
- 32
- Registration Number
- NCT02974166
- Locations
- 🇧🇷
Brazilian Institute of Osteopathy, Porto Alegre, Rio Grande do Sul, Brazil
Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment
- Conditions
- Musculoskeletal Pain
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- EMS
- Target Recruit Count
- 414
- Registration Number
- NCT02862977
- Locations
- 🇧🇷
Marcio Antonio Pereira Clinica de Endocrinologia, São José dos Campos, São Paulo, Brazil
🇧🇷Associação dos funcionários públicos do estado do RGS, Porto Alegre, RS, Brazil
🇧🇷Centro de Medicina Reprodutiva Dr Carlos Isaia Filho, Porto Alegre, RS, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.